Caris Life Sciences, Inc. (CAI)Healthcare | Biotechnology | Irving, United States | NasdaqGS
21.15 USD
+0.75
(3.676%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 21.36 +0.21 (0.993%) ⇧ (April 17, 2026, 7:33 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:35 p.m. EDT
Despite negative earnings (forever P/L) and poor short-term forecasting models (-1.2% predicted move), Caris (CAI) presents a flawed but intriguing long-term asymmetric bet. The market has punished the stock for being below its 200-day average, yet the options market is betting hard on a multi-year recovery. The fundamental picture remains weak with 74% debt-to-equity and 56x forward PE based on losses, offering no margin of safety. However, the 'hot take' at the bottom of the well is the 13x analyst consensus 'Strong Buy' rating, which is rare for a biotech in distress, suggesting a catalyst (e.g., drug approval or data readout) could be concealed within the upcoming earnings report. Buy only on speculation of that catalyst, not for quarterly results. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.258492 |
| AutoETS | 0.269685 |
| AutoTheta | 0.269835 |
| AutoARIMA | 0.270685 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 2.27 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.006 |
| Excess Kurtosis | 1.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 74.083 |
| Revenue per Share | 4.856 |
| Market Cap | 5,976,564,736 |
| Forward P/E | 56.62 |
| Profit Margins | -8.39% |
| Website | https://www.carislifesciences.com |
As of April 18, 2026, 11:35 p.m. EDT: Options flow shows a distinct bullish bias on the long duration (>6 months). Call OI is heavily skewed out-of-the-money (OTM) with massive positioning at strikes 30.0 and 35.0 for the July and October 2026 expirations, indicating speculation of a significant 50%+ move by year-end. Conversely, put positioning is front-loaded for downside protection below the current price (15.0–20.0 strikes for May/July), suggesting investors are hedging against a potential immediate 10-20% correction, but are confident of a recovery in 6+ months. The ATM call premium is relatively cheap compared to the depth of OTM call interest.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.24464285 |
| Address1 | 750 West John Carpenter Freeway |
| Address2 | Suite 800 |
| All Time High | 42.5 |
| All Time Low | 16.28 |
| Ask | 22.68 |
| Ask Size | 2 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 1,818,290 |
| Average Daily Volume3 Month | 2,426,870 |
| Average Volume | 2,426,870 |
| Average Volume10Days | 1,818,290 |
| Bid | 19.6 |
| Bid Size | 2 |
| Book Value | 2.043 |
| City | Irving |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 21.15 |
| Current Ratio | 7.848 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 21.46 |
| Day Low | 20.95 |
| Debt To Equity | 74.083 |
| Display Name | Caris Life Sciences |
| Earnings Call Timestamp End | 1,772,141,400 |
| Earnings Call Timestamp Start | 1,772,141,400 |
| Earnings Timestamp | 1,772,139,600 |
| Earnings Timestamp End | 1,778,011,200 |
| Earnings Timestamp Start | 1,778,011,200 |
| Ebitda | 67,728,000 |
| Ebitda Margins | 0.083409995 |
| Enterprise To Ebitda | 82.768 |
| Enterprise To Revenue | 6.903 |
| Enterprise Value | 5,605,682,176 |
| Eps Current Year | 0.14008 |
| Eps Forward | 0.37354 |
| Eps Trailing Twelve Months | -3.22 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 866 479 4925 |
| Fifty Day Average | 19.4216 |
| Fifty Day Average Change | 1.7283993 |
| Fifty Day Average Change Percent | 0.08899366 |
| Fifty Two Week Change Percent | -24.464285 |
| Fifty Two Week High | 42.5 |
| Fifty Two Week High Change | -21.35 |
| Fifty Two Week High Change Percent | -0.50235295 |
| Fifty Two Week Low | 16.28 |
| Fifty Two Week Low Change | 4.869999 |
| Fifty Two Week Low Change Percent | 0.29913998 |
| Fifty Two Week Range | 16.28 - 42.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,750,253,400,000 |
| Float Shares | 97,083,157 |
| Forward Eps | 0.37354 |
| Forward P E | 56.620438 |
| Free Cashflow | 53,502,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,846 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.66628 |
| Gross Profits | 541,038,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.48583 |
| Held Percent Institutions | 0.51936 |
| Implied Shares Outstanding | 282,579,919 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-06-18 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas. |
| Long Name | Caris Life Sciences, Inc. |
| Market | us_market |
| Market Cap | 5,976,564,736 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_285971879 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -537,956,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,976,565,286 |
| Number Of Analyst Opinions | 13 |
| Open | 21.0 |
| Operating Cashflow | 83,155,000 |
| Operating Margins | 0.30186 |
| Payout Ratio | 0.0 |
| Phone | 866 771 8946 |
| Post Market Change | 0.21000099 |
| Post Market Change Percent | 0.99291253 |
| Post Market Price | 21.36 |
| Post Market Time | 1,776,468,827 |
| Previous Close | 20.4 |
| Price Eps Current Year | 150.98514 |
| Price Hint | 2 |
| Price To Book | 10.352423 |
| Price To Sales Trailing12 Months | 7.360002 |
| Profit Margins | -0.083850004 |
| Quick Ratio | 7.163 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.38462 |
| Region | US |
| Regular Market Change | 0.75 |
| Regular Market Change Percent | 3.67647 |
| Regular Market Day High | 21.46 |
| Regular Market Day Low | 20.95 |
| Regular Market Day Range | 20.95 - 21.46 |
| Regular Market Open | 21.0 |
| Regular Market Previous Close | 20.4 |
| Regular Market Price | 21.15 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,121,875 |
| Return On Assets | 0.03838 |
| Return On Equity | -0.45374 |
| Revenue Growth | 1.254 |
| Revenue Per Share | 4.856 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 282,579,919 |
| Shares Percent Shares Out | 0.0364 |
| Shares Short | 10,294,979 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 6,509,779 |
| Short Name | Caris Life Sciences, Inc. |
| Short Percent Of Float | 0.0705 |
| Short Ratio | 3.78 |
| Source Interval | 15 |
| State | TX |
| Symbol | CAI |
| Target High Price | 38.0 |
| Target Low Price | 21.0 |
| Target Mean Price | 29.69231 |
| Target Median Price | 30.0 |
| Total Cash | 798,569,024 |
| Total Cash Per Share | 2.826 |
| Total Debt | 427,686,016 |
| Total Revenue | 812,033,024 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.22 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 26.9243 |
| Two Hundred Day Average Change | -5.7742996 |
| Two Hundred Day Average Change Percent | -0.21446425 |
| Type Disp | Equity |
| Volume | 1,121,875 |
| Website | https://www.carislifesciences.com |
| Zip | 75,039 |